Skip to main content
DeutschDE
European Commission logo print header
Inhalt archiviert am 2024-04-19

Peptides for the early detection and vaccination against tuberculosis and leprosy

Ziel



The nature of T cell immune reactions decides between the
protective or pathogenic outcome following tuberculous infection. Therefore, understanding of the T cell mediated mechanisms is the prerequisite for the design of more efficient control of the disease. The proposed research will be focused on the specificity of T cells, relating to small peptides and to the associated cellular immune functions. The short-term objective is aimed at erly detection of tuberculosis (and leprosy), which would help to reduce trasmission of infection in the population following early chemotherapy. The medium/long-term objective is aimed at the identification of small peptide subunits for prophylactic vaccination. This concept is justified by the knowledge that the BCG vaccin although sensitising to many antigens, is poorly effective.
The proposed programme has a range of activities from clinical evaluation and development of diagnostic peptides to exploratory research on the identification of immunogenic peptides in infected mammalian cells. Whilst the clinical evaluation must be performed in a disease endemic country, the peptide elution work needs to be done in a high technology experienced institution.
Each of the participating three European and three Indian teams has complementary expertise, based on several years of prominent achievement in the field. The London team has identified immunodominant peptides and their clinical evaluation will be done in Delhi and Agra. Liposomised peptides for skin testing will be developed in Lucknow. The Stockholm participant will use complex new equpment and technology to identify immunogenic peptides in infected mammalian cells. Peptides generated by empirical mapping, computer prediction and cell elution strate-ies will be evaluated bY the Leiden participant who is experienced in T cell cloning genetic analysis and cytokine assays. The protective ca-acit- of candidate
peptides will be tested in an adoptive animal model, developed in London. Transfer of information and technology between the participants will be of major mutual benefit. The Indian participants are from leading major Institutions, all of different provenance, who are in a position to benefit significantly from the results which are expected in outcome to this

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Data not available

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

CSC - Cost-sharing contracts

Koordinator

MRC Clinical Sciences Centre
EU-Beitrag
Keine Daten
Adresse
Hammersmith Hospital Du Cane Road
W12 0NN London
Vereinigtes Königreich

Auf der Karte ansehen
Gesamtkosten
Keine Daten

Beteiligte (5)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 9 Juni 1995

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/TS3*940304/de

European Union, 2024